SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithkline Pharma decides to enter into India-specific alliance

04 Feb 2013 Evaluate

Multinational drug-maker, GlaxoSmithkline Pharmaceuticals has decided to enter into India-specific alliance, which will be for a product that is a new area for the company. With this decision to bring in niche products from other drug-majors through in-licensing deals, the company aims to expand the operations locally.

The entity’s existing alliances in the local market include ones with Daiichi-Sankyo on hypertensive Olmesartan Medoxomil, and with Astellas on anti-fungal drug Micafungin.

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×